Prophylactic intranasal treatment with fragments of 1,3-β-glucanase olive pollen allergen prevents airway inflammation in a murine model of type I allergy

International Archives of Allergy and Immunology

Volumn 139, Issue 3, 2006, Pages 175-180

  Palomares, O ^a   Batanero, E ^a   Canamero M ^b   Villalba, M ^a   Rodriguez R ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL RUBER INTERNACIONAL   (Spain)

Author keywords

1,3 Glucanase; Animal model; Olive pollen allergy; Prophylactic intranasal treatment; Recombinant allergen

Indexed keywords

1,3 BETA GLUCANASE OLIVE POLLEN ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2; POLLEN ANTIGEN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

AIRWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNIZATION; LUNG; LUNG LAVAGE; LYMPHOCYTIC INFILTRATION; MICROSCOPY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OLIVE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SENSITIZATION; TH2 CELL;

ADMINISTRATION, INTRANASAL; ALLERGENS; ANIMALS; BETA-GLUCOSIDASE; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; LUNG; MICE; MICE, INBRED BALB C; OLEA; PEPTIDE FRAGMENTS; PLANT PROTEINS; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL;

EID: 33344457434     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091162     Document Type: Article

References (26)

1. Liccardi G, D'Amato M, D'Amato G: Oleaceae pollinosis. Int Arch Allergy Immunol 1996;111:210-217.
2. Manousis T, Moore NF: Exploited plants: the olive tree. Biologist 1988;35:7.
3. Lombardero M, Obispo T, Calabozo B, Lezaún A, Polo F, Barber D: Cross-reactivity between olive and other species. Role of Ole e 1-related proteins. Allergy 2002;57(suppl 71):29-34.
4. Florido JF, González P, Sáenz de San Pedro B, Quiralte J, Arias de Saavedra JM, Peralta V, et al: High levels of Olea europaea pollen and relation with clinical findings. Int Arch Allergy Immunol 1999;119:133-137.
5. Rodríguez R, Villalba M, Monsalve RI, Batanero E: The spectrum of olive pollen allergens, Int Arch Allergy Immunol 2001;125:185-195.
6. Rodríguez R, Villalba M, Batanero E, Gónzalez EM, Monsalve RI, Huecas S, Tejera ML, Ledesma A: Allergenic diversity of the olive pollen. Allergy 2002;57(suppl 71):6-16.
7. Barral P, Batanero E, Palomares O, Quiralte J, Villalba M, Rodríguez R: A major allergen from pollen defines a novel family of plant proteins and shows intra- and interspecies cross-reactivity. J Immunol 2004;172:3644-3651.
8. Huecas S, Villalba M, Rodríguez R: Ole e 9, a major olive pollen allergen is a 1,3-β-glucanase. J Biol Chem 2001;276:27959-27966.
9. Palomares O, Villalba M, Quiralte J, Polo F, Rodrißguez R: 1,3-β-Glucanases as candidates in latex-pollen-vegetable food cross-reactivity. Clin Exp Allergy 2005;35:345-351.
10. Palomares O, Villalba M, Rodríguez R: The C-terminal segment of the 1,3-β-glucanase Ole e 9 from olive pollen is an independent domain with allergenic activity. Expression in Pichia pastoris and characterization. Biochem J 2003;369:593-601.
11. Guerra F, Daza JC, Almeda E: Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment. J Investig Allergol Clin Immunol 2003;13:108-117.
12. González P, Florido F, Sáenz de San Pedro B, de la Torre F, Rico P, Martin S: Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment. J Investig Allergol Clin Immunol 2002;12:263-271.
13. Hejjaoui A, Ferrando R, Dhivert H, Michel FB, Bousquet J: Systemic reactions occurring during immunotherapy with standardized pollen extracts. Allergy Clin Immunol 1992;89:925-933.
14. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H: The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999;29:896-904.
15. Kagi MK, Wuthrich B: Different methods of local allergen-specific immunotherapy. Allergy 2002;57:379-388.
16. Wiedermann U, Jahn-Schmid B, Repa A, Kraft D, Ebner C: Modulation of an allergic immune response via the mucosal route in a murine model of inhalative type-I allergy. Int Arch Allergy Immunol 1999;118:129-132.
17. Winkler B, Baier K, Wagner S, Repa A, Eichler HG, Scheiner O, Kraft D, Wiedermann U: Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy 2002;32:30-36.
18. Batanero E, Barral P, Villalba M, Rodriguez R: Sensitization of mice with olive pollen allergen Ole e 1 induces a Th2 response. Int Arch Allergy Immunol 2002;127:269-275.
19. Valenta R: The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446-453.
20. Hamelmann E, Takeda K, Oshiba A, Gelfand EW: Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness - a murine model. Allergy 1999;54:297-305.
21. Hamelmann E, Takeda K, Schwarze J, Vella AT, Irvin CG, Gelfand EW: Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am J Respir Cell Mol Biol 1999;21:480-489.
22. Jarniki AG, Takao T, Wayne RT: Inhibition of mucosal and systemic Th2-type immune responses by intranasal peptides containing a dominant T cell epitope of the allergen Der p 1. Int Immunol 2001;13:1223-1231.
23. Wiedermann U, Herz U, Baier K, Vrtala S, Neuhaus-Steinmetz U, Bohle B, et al: Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents sensitization and airway inflammation in mice. Int Arch Allergy Immunol 2001;126:68-77.
24. Hufnagl K, Winkler B, Baier K, Kraft D, Valenta R: Induction of mucosal tolerance by coapplication of recombinant Bet v 1, the major birch pollen allergen, recombinant Phl p 1 and Phl p 5, major grass pollen allergens, in polysensitized mice. Allergy 2002;57(suppl 73):49.
25. Hufnagl K, Winkler B, Focke M, Valenta R, Scheiner O, Renz H, et al: Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. J Allergy Clin Immunol 2005;116:370-376.
26. Herz U, Renz H, Wiedermann U: Animal models of type I allergy using recombinant allergens. Methods 2003;32:271-280.